NEW YORK (TheStreet) -- In my opinion, Federal Reserve policy failed as soon as the FOMC cut the federal funds rate below 3% on March 18, 2008, to 2.25%. It was Dec. 16, 2008, when the Fed cut this rate to 0%, where it could remain for years to come if Janet Yellen becomes the next Fed chairman in early 2014.
The Fed's quantitative easing programs began in late November 2008 when the Federal Reserve Open Market Trading Desk in New York began to purchase $600 billion in mortgage-backed securities. Two years later the Fed announced another round of purchases and this time it was $600 billion in longer-dated U.S. Treasuries by the end of second quarter of 2011. This second wave was dubbed QE2. [Read: Before Buying ConAgra, Read the Label]
Top 5 Clean Energy Stocks To Own For 2015: American International Group Inc.(AIG)
American International Group, Inc. is an international insurance organization. The company operates property and casualty insurance networks worldwide and conducts activities in the U.S. life insurance and retirement services industry. It also involves in commercial aircraft leasing and residential mortgage guaranty insurance businesses. The company, through Chartis Inc., provides various property and casualty insurance products under commercial and consumer categories worldwide. These products include surplus lines, executive liability/directors? and officers? liability, employment practices, excess casualty, and travel/assistance lines. American International Group, through SunAmerica Financial Group, offers a suite of life insurance and retirement products and services, including term life, universal life, accident and health, fixed and variable deferred annuities, fixed payout annuities, mutual funds, and financial planning products and services to individuals and grou ps in the United States. The company, through International Lease Finance Corporation, operates as an aircraft lessor that acquires commercial jet aircraft from various manufacturers and other parties, and leases those aircraft to airlines worldwide. It also sells aircraft from its fleet to other leasing companies, financial services companies, and airlines, as well as provides management services to third-party owners of aircraft portfolios. American International Group, through United Guaranty Corporation, issues residential mortgage guaranty insurance that covers mortgage lenders from the first loss for credit defaults on high loan-to-value conventional first-lien mortgages for the purchase or refinance of one- to four-family residences in the U.S. and internationally. The company was founded in 1967 and is based in New York, New York.
Advisors' Opinion:- [By With assistance from Sofia Horta e Costa]
AIG (AIG), the insurer that repaid a U.S. rescue last year, declined 6.5 percent to $48.28, headed for the lowest close in a year. Premium revenue at the property-casualty division fell 3.7 percent to $8.43 billion in the third quarter, the company said in a statement late yesterday. Third-quarter net income rose to $2.17 billion, or $1.46 a share, from $1.86 billion, or $1.13 a year earlier, New York-based AIG said.
- [By Amanda Alix]
So, tempers were high, certainly. Smith may have misunderstood, or Laughlin may be prevaricating. If PIMCO executives heard the claim, then surely so did AIG (NYSE: AIG ) . The megainsurer has been gunning for B of A on this issue, as well as others concerning toxic mortgage-backed securities it claims that the bank sold under less than candid circumstances. That testimony should be very interesting, indeed.
Hot Electric Utility Stocks To Own Right Now: Bazaarvoice Inc (BV)
Bazaarvoice, Inc., incorporated on May 25, 2005, connects businesses together to amplify the authentic voices of people where they shop. The Company�� solutions, which are primarily provided through Software as a Service (SaaS) platform, enable clients to capture and display online word of mouth about specific products and services, channel content into all the places where it will influence a purchase both within and outside its network, which it refers to as syndication, and use business insights so they can act on what consumers want.
Bazaarvoice Conversations Platform
The Company�� Conversations platform provides capabilities to capture, manage and display online word of mouth. Consumers interact with its solutions as they view or author consumer reviews, questions, photos, videos, long-format narratives and other forms of consumer-generated content. Content that is displayed by its Conversations platform is styled to match its clients��brand, preserving important branding elements of its clients��businesses. Content collected and managed by its Conversations platform is used by its clients in a range of applications, including their online Websites, mobile-optimized Websites, mobile applications, social networks, in-store kiosks, physical in-store displays, printed flyers, email and other forms of online and offline media. The Company�� Conversations platform allows clients to capture, manage and display consumer reviews about their products and services on their Websites and mobile-optimized Websites; allows clients to facilitate question and answer conversations between consumers, or between consumers and brand representatives, on their Websites; allows clients to collect consumer testimonials about their products and services and display these stories on their Websites; enables consumers to read or write reviews, product questions, product answers, or stories on its clients��pages on social networking Websites and easily share this content with the peopl! e they influence the most-their social network friends or followers, and provides third-party developers with tools to build products or extend its platform on behalf of its clients, which enables the Company to expand the use of its platform by leveraging applications built by third-party developers.
Bazaarvoice Connections Solutions
The Company�� Conversations clients are connected through its SaaS platform to form a network. The Company offers network syndication and brand engagement solutions to facilitate the sharing of online word of mouth among its clients and to enable brands to directly interact with consumers on its retail clients��Websites. BrandVoice enables brands to enter into distribution relationships allowing them to display review content from their brand Websites on retail Websites within its network, which it refers to as syndication. BrandAnswers enables brands to interact directly with consumers on retail websites within its network to answer questions and provide suggestions on alternative products that may better meet that consumer�� needs. Brand Response enables brands to interact with consumers by responding to reviews posted on retail Websites within its network.
Bazaarvoice Analytics Solutions
The Company�� Conversations platform includes its Intelligence solution, which is it enhanced analytics solution, and a Workbench Analytics solution, which provides analytics and self-service administration tools. Intelligence allows clients to derive sophisticated market, consumer and product insights in a timely manner from the underlying data it collects on their behalf through its platform. Workbench Analytics provides basic analytics capabilities that allow its clients to generate reports highlighting simple ratings trends, text analysis and product and service issue identification.
Bazaarvoice Media
The Company�� Bazaarvoice Media sells advertising on behalf of retailers, brands and agencie! s, and pr! ovides capabilities that incorporate consumers��authentic opinions in advertising campaigns, creating advertisements that are trusted, relevant and targeted. Bazaarvoice Media sells advertising on retail Websites, utilizing its relationships and knowledge of the intricacies of the retail environment. It develops custom programs for brands to reach consumers while they are in the shopping environment, while also selling to non-retail brands, such as within the automotive and financial industries, that wish to reach the engaged shopper within this channel. Word of Mouth Advertisements provides brands with the ability to increase engagement with their advertising through the inclusion of authentic consumer sentiment. Mobile Advertising enables brands to reach consumers on their mobile devices.
The Company competes with Pluck, Reevoo, Gigya, Viewpoints, Google and Facebook.
Advisors' Opinion:- [By Roberto Pedone]
Another earnings short-squeeze prospect is Bazaarvoice (BV), a provider of social commerce software solutions, which is set to release numbers on Wednesday after the market close. Wall Street analysts, on average, expect Bazaarvoice to report revenue of $44.12 million on a loss of 8 cents per share.
The current short interest as a percentage of the float for Bazaarvoice is very high at 14.4%. That means that out of the 41.18 million shares in the tradable float, 6.33 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 11.6%, or by 656,000 shares. If the bears are caught pressing their bets into a bullish quarter, then shares of BV could rip sharply higher post-earnings as the shorts rush to cover some of their bets.
From a technical perspective, BV is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been trending sideways inside of a consolidation pattern for the last month and change, with shares moving between $10.15 on the downside and $11.50 on the upside. Any high-volume move above the upper-end of its recent range post-earnings could trigger a major breakout trade for shares of BV.
If you're bullish on BV, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $11.35 to $11.50 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 661,797 shares. If that breakout triggers, then BV will set up to re-test or possibly take out its next major overhead resistance levels at $13 to $14 a share.
I would simply avoid BV or look for short-biased trades if after earnings it fails to trigger that breakout and then drops back below its 50-day at $10.34 a share and then below some key near-term support at $10.15 a share with high volume. If we get that m
Hot Electric Utility Stocks To Own Right Now: TotalFinaElf S.A.(TOT)
TOTAL S.A., together with its subsidiaries, operates as an integrated oil and gas company worldwide. The company operates through three segments: Upstream, Downstream, and Chemicals. The Upstream segment engages in the exploration, development, and production of oil and natural gas. It also involves in the transportation, trade, and marketing of natural gas and liquefied natural gas (LNG), as well as in LNG re-gasification and natural gas storage operations. In addition, this segment engages in the shipping and trade of liquefied petroleum gas (LPG); power generation from gas-fired power plants, nuclear, or renewable energies; production, trade, and marketing of coal, as well as in solar power systems and technology operations. As of December 31, 2010, it had combined proved reserves of 10,695 Mboe of oil and gas. The Downstream segment involves in refining, marketing, trading, and shipping crude oil and petroleum products. It also produces a range of specialty products, s uch as lubricants, LPG, jet fuel, special fluids, bitumen, marine fuels, and petrochemical feedstock. This segment holds interests in 24 refineries located in Europe, the United States, the French West Indies, Africa, and China, as well as operates a network of 17,490 service stations. The Chemicals segment produces base chemicals, including petrochemicals and fertilizers, as well as engages in rubber processing, resins, adhesives, and electroplating activities. TOTAL S.A. was founded in 1924 and is based in Paris, France.
Advisors' Opinion:- [By Dan Caplinger]
But another reason for the rise is that so many Europe-based companies have global exposure that never truly justified a big European discount. France's Total (NYSE: TOT ) and Norway's Statoil (NYSE: STO ) both found themselves trading at discounts to other global energy players, despite the fact that both Total and Statoil have massive exposure to international projects in the same areas around the world as U.S. and other global energy players. Similarly, in the pharmaceutical industry, Switzerland's Novartis (NYSE: NVS ) didn't do as well as some of its U.S. rivals. Yet Novartis hasn't really faced any tougher a road than its global counterparts in fighting against the industrywide patent cliff and coming up with new promising treatments.
Hot Electric Utility Stocks To Own Right Now: Roche Holding AG (RHHBY)
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.
During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.
In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.
Pharmaceuticals
Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.
Diagnostics
Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.
Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.
Advisors' Opinion:- [By James E. Brumley]
I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).
- [By Bryan Murphy]
When most investors think of cancer stocks, names like Amgen, Inc. (NASDAQ:AMGN) or Roche Holding Ltd. (OTCMKTS:RHHBY) come to mind. And to be fair, they're both top-of-mind names for good reasons. Five of the world's top-ten selling cancer drugs are from Roche Holding, and Amgen is the world's biggest biotech company; it just spent $10 billion on the acquisition of an entire company almost to add just one cancer therapy to its library. Thing is, while Roche Holding Ltd. and Amgen, Inc. make top-notch drugs to treat cancer once acquired, neither actually does anything to prevent the development of cancer through metastasization. Indeed, the prevention of the spread of cancer isn't on the biopharma industry's radar at all, save one company - a little outfit called MetaStat Inc. (OTCBB:MTST).
- [By Sean Williams]
Dendreon's likely partner
While it's purely speculation on my part, I believe the most likely marketing partner would be one of Europe's premier cancer-fighting companies, Roche (NASDAQOTH: RHHBY ) . - [By Ben Levisohn]
Shares of Regeneron have jumped 3.5% to $316.39–and the S&P 500′s best performer today. Novartis (NVS), which makes Lucentis, has dipped 0.5% to $76.73, while Roche (RHHBY), which makes Avastin, has gained 0.2% to $67.54. Vertex Pharmaceuticals (VRTX), meanwhile, has gained 0.9% to $76.77, making it the 10th best perform in the S&P 500.
Hot Electric Utility Stocks To Own Right Now: TeliaSonera AB (TLSN)
TeliaSonera AB is a Sweden-based company engaged in the provision of network access and telecommunication services to individual and business customers. The Company is organized into four business segments: the Mobile Services segment provides mobile services, which include mobile voice and data, mobile content, Wireless Local Area Network (WLAN) Hotspots, mobile broadband and Wireless Office to the consumer and enterprise markets; the Broadband Services segment provides services for connecting homes and offices, including broadband over copper, fiber and cable, television (TV), voice over Internet, home communications services, Internet Protocol- Virtual Private Network (IP-VPN)/Business Internet, leased lines and traditional telephony; the Eurasia segment comprises mobile operations in Kazakhstan, Azerbaijan, Uzbekistan, Tajikistan, Georgia, Moldova and Nepal, and the Other operations segment comprises Other Business Services, TeliaSonera Holding and Corporate functions. Advisors' Opinion:- [By Jonathan Morgan]
TeliaSonera (TLSN) slid 1.9 percent to 47.56 Swedish kronor. Solidium Oy, Finland�� equity-asset manager, sold 1.6 percent of shares in the Stockholm-based company in an accelerated book building to institutional investors, it said in a statement.
Hot Electric Utility Stocks To Own Right Now: Realty Income Corporation(O)
Realty Income Corporation engages in the acquisition and ownership of commercial retail real estate properties in the United States. The company leases its retail properties primarily to regional and national retail chain store operators. As of December 31, 2006, it owned 1,955 retail properties located in 48 states, covering approximately 16.7 million square feet of leasable space. The company also held a portfolio of 60 properties through its wholly owned subsidiary, Crest Net Lease, Inc. (Crest), as of the above date. Realty Income Corporation has elected to be treated as a real estate investment trust (REIT) under the Internal Revenue Code. As a REIT, it would not be subject to federal income taxes provided it distributes at least 90% of its taxable income to its shareholders. The company was founded in 1969 and is based in Escondido, California.
Advisors' Opinion:- [By David Dittman]
Answer: Realty Income Corp (NYSE: O) and WP Carey & Co (NYSE: WPC), up to 45 and 55, respectively.
Question: Bell Alliant Inc (TSX: BA, OTC: BLIAF) has been weak/flat even though the overall market has been strong. Great dividend; is it solid? Is it worth continuing to hold?
- [By Rubicon Associates]
Going a little further back, we see Realty Income (O) becoming the exit strategy for American Realty Capital Trust (here):
Premium to Share Price and Asset Values This transaction enables the shareholders of American Realty Capital Trust to capitalize on the recent upward price movement of the shares of ARCT, and to achieve a premium valuation for their shares. Furthermore, ARCT's assets were acquired at an opportune time in the market. This transaction allows ARCT's shareholders to realize a premium over their purchase price.
- [By Brad Thomas]
It seems that Mr. Market has seen the mispriced risk associated with MPW's differentiated higher risk value proposition. Simply said, it makes no sense to invest in a REIT that pays out a dividend yield of 5.3% when it's acquiring properties at 9%. In other words, I can buy shares in Realty Income (O) today ($47.73) and get a 4.7% dividend yield with much less risk.
No comments:
Post a Comment